Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma
Petra Rietschel(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Katherine Smith(Nationwide Children's Hospital), Klaus J. Busam(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic), Scott R. Gerst(Memorial Sloan Kettering Cancer Center), Irene Orlow(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Achim A. Jungbluth(Gynecologic Oncology Group)
Cited by 73
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k